Annual Secretarial Compliance Report
Awaiting price reaction for this filing.
Eris Lifesciences has submitted its Annual Secretarial Compliance Report to BSE and NSE, as required under Regulation 24(A) of SEBI's Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015. The report was issued by Practicing Company Secretary Ravi Kapoor (FCS 2587) of Ravi Kapoor & Associates, Ahmedabad, dated 23 May 2025. The PCS examined the company's filings, website, records, and submissions for FY 2024-25 against multiple SEBI regulations including LODR, Insider Trading, Takeover, and Share-Based Employee Benefits rules. The company was found fully compliant across all 13 checklist areas, with no deviations, no SEBI or stock exchange actions, no director disqualifications, and no prior observations pending. Buyback and Delisting regulations were noted as not applicable during the year.
This is a routine annual regulatory filing with no negative findings — it confirms clean compliance status and is unlikely to move the stock. No material action, penalty, or new disclosure is triggered for shareholders.